Clinical Trials Logo

Clinical Trial Summary

The purpose of this investigation is to evaluate the ability of maternal aspirin (ASA) therapy to prevent preterm birth for fetal indications prior to 32 weeks gestation in women with early onset Fetal Growth Restriction (FGR). Aspirin is a commonly used medication that blocks blood platelets from clumping. Aspirin crosses the placenta in a dose dependent mode. There is preliminary evidence in smaller studies that aspirin can block fetal platelet clumping and, therefore, slow down the progression of placental disease under specific circumstances. The optimal time for aspirin to work is when the fetus' placental dysfunction is still mild. The goal of this research study is to show if fetuses that receive aspirin through maternal intake at a dose shown to affect fetal platelet aggregation will be less likely to deliver before 32 weeks for fetal deterioration. The outcomes of patients that receive aspirin will be compared to women that receive standard FGR management but do not take any aspirin. The decision if a study participant receives aspirin or not will be randomly picked. Such a research study is called a randomized controlled trial.

Clinical Trial Description

Early onset FGR requiring preterm delivery by 32 weeks gestation complicates 1-5% of pregnancies and is an important health problem. Over 60% of children have long-term health consequences after being delivered for early onset FGR. There is no prenatal treatment for fetal growth restriction. The current management of FGR consists of fetal surveillance to detect a decline in the baby's health and deliver when this can be safely done. In a large number of early onset FGR, premature delivery is required to prevent the fetus from becoming more compromised or even dying in the womb. Placental dysfunction leading to early onset FGR is characterized by changes to the blood vessels of the placenta, leading to a decline in the amount of blood flow to the placenta. The arteries that run in the umbilical cord of the fetus (umbilical arteries) are important for nutrient exchange between the fetal and placental circulation. Many fetuses with early onset FGR have elevated resistance in the blood vessels entering the placenta. This results in decreased blood flow in the umbilical artery (UA). The blood flow in the umbilical artery is evaluated by a specialized ultrasound technique called Doppler ultrasound. Doppler ultrasound of the umbilical arteries examines the blood flow to see if there is evidence of abnormal blood flow into the placenta. When the amount of blood flow at the end of every pulse decreases, it is classified as elevated UA blood flow resistance. When the blood flow briefly pauses at the end of each pulse, this is called absent end-diastolic velocity (AEDV) or UA AEDV. When the blood flow reverses at the end of each pulse, this is called reversed end-diastolic velocity (UA REDV). In fetuses with elevated UA blood flow, the placenta can usually supply enough nutrients and oxygen for at least 9 weeks. After that time, delivery is typically required. The worsening of blood flow to UA AEDV, or even UA REDV, increases the risk for fetal deterioration and preterm birth within the next 2-6 weeks. Approximately, 80% of early onset FGR fetuses progress to UA AEDV, or even UA REDV, and then require delivery by 32 weeks. There is no treatment that can stop this progression which is of critical importance in determining how much time is left for the fetus before delivery will be necessary. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04557475
Study type Interventional
Source Johns Hopkins University
Status Withdrawn
Phase Phase 3
Start date June 11, 2022
Completion date June 11, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT04502823 - Management of Fetal Growth Restriction at Term: Angiogenic Factors Versus Feto-placental Doppler N/A
Not yet recruiting NCT03625518 - Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes Early Phase 1
Completed NCT05176041 - SLE Therapy Changes in Pregnancy and Relation to Pregnancy Outcome
Completed NCT02379728 - Ghana PrenaBelt Trial: A Positional Therapy Device to Reduce Still-Birth N/A
Completed NCT01695070 - Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies Phase 4
Completed NCT01352234 - Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia Phase 4
Completed NCT04289350 - Day to Day Variation in Fetal Heart Rate Variability
Recruiting NCT03662178 - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Recruiting NCT05023161 - Non-invasive Placental Chromosome Exploration of Intrauterine Growth Restriction
Completed NCT02590536 - A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction Phase 3
Not yet recruiting NCT05029778 - Arginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth Curve Phase 4
Recruiting NCT05576207 - BEP Supplementation Research in Bangladesh (JiVitA-BEP-IR) N/A
Active, not recruiting NCT05160649 - Effect of Covid 19 Infection on Fetomaternal Outcome
Completed NCT02280031 - Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial. Phase 2
Recruiting NCT04389099 - MRI Angiography of Physiological and Pathological Pregnancy Placentas Ex-vivo
Recruiting NCT06039319 - Acute Effects of Maternal Exercise and the Growth Restricted Pregnancy
Recruiting NCT05651347 - Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction Phase 3
Recruiting NCT02336243 - A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders Phase 3
Active, not recruiting NCT01594463 - Routine Ultrasound Screening in the Third Trimester N/A